MedPath

Found 550128 clinical trials

Sort by:

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

Not Applicable

Not yet recruiting

Conditions: NSCLC (Non-small Cell Lung Cancer)

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Tau-MEDICAL Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT07122258

Implementing a Therapy for Complex Trauma in French-Speaking Settings

Not Applicable

Completed

Conditions: Borderline Personality Disorder (BPD)
Complex Post-Traumatic Stress Disorder (CPTSD)
Post-Traumatic Stress Disorder, PTSD

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Ciusss de L'Est de l'Île de Montréal

Target Recruit Count: 15

Registration Number: NCT07123974

Locations: 🇨🇦
Institut universitaire en santé mentale de Montréal, Montréal, Quebec, Canada

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Not Applicable

Not yet recruiting

Conditions: Autoimmune Diseases

Interventions: Biological: GT719 Injection

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Grit Biotechnology

Target Recruit Count: 10

Registration Number: NCT07122076

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, China

Validity and Reliability of the 6-Minute Pegboard and Ring Test in Interstitial Lung Disease

Active, not recruiting

Conditions: Interstitial Lung Diseases (ILD)

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Marmara University

Target Recruit Count: 27

Registration Number: NCT07122141

Locations: 🇹🇷
Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 364

Registration Number: NCT07123649

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Monitoring the Response of Combination Ursodiol and Seladelpar Treatment

Not yet recruiting

Conditions: Primary Biliary Cholangitis

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Methodist Health System

Target Recruit Count: 100

Registration Number: NCT07122206

Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation

Not Applicable

Recruiting

Conditions: Persistent Atrial Fibrillation

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 384

Registration Number: NCT07122336

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

Not Applicable

Completed

Conditions: Sepsis
Bacterial Infection

Interventions: Drug: Meropenem Infusion

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Pakistan Navy Station Shifa Hospital

Target Recruit Count: 150

Registration Number: NCT07122596

Locations: 🇵🇰
Pns Shifa Hospital, Karachi., Karachi, Sindh, Pakistan

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Not Applicable

Recruiting

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions: Drug: FL115
Drug: FL115+BCG

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Suzhou Forlong Biotechnology Co.,Ltd,

Target Recruit Count: 80

Registration Number: NCT07122414

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

and more 8 locations

Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure

Not Applicable

Not yet recruiting

Conditions: Atrial Fibrillation
Atrial Flutter
Tachycardia, Supraventricular
Heart Septal Defects, Atrial

Interventions: Drug: Beta-blocker treatment group
Drug: Non-treatment group

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Yonsei University

Target Recruit Count: 350

Registration Number: NCT07123506

Locations: 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of

AI-Powered Research

Premium Access

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

Implementing a Therapy for Complex Trauma in French-Speaking Settings

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Validity and Reliability of the 6-Minute Pegboard and Ring Test in Interstitial Lung Disease

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Monitoring the Response of Combination Ursodiol and Seladelpar Treatment

Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure

Product

Company

Legal